TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 40.74 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $11.407 million which beat the analyst consensus estimate of $10.267 million by 11.10 percent. This is a 1.73 percent increase over sales of $11.213 million the same period last year.